Publications
Sorted by date
- Personalized vaccine TG4050 induces polyepitopic immune responses against private neoantigens in resected HPV negative head and neck cancers
A. Lalanne, et al.
AACR 2024
Abstract available on the AACR website – Download the poster
Poster Presentation
- Phase Ib/II trial of tipapkinogene sovacivec (TG4001), a therapeutic human papillomavirus 16-vaccine, in combination with avelumab in patients with advanced human papillomavirus 16-positive cancers
C. Le Tourneau, et al.
European Journal of Cancer, July 2023 (191)
Access the article here
Publication - Safety and Immunogenicity of TG4050; a personalized cancer vaccine in head and neck carcinoma
C. Ottensmeier, et al.
ASCO 2023
Abstract available on the ASCO website – Download the abstract and the poster
Poster Presentation - Immunogenicity and clinical activity of Tipapkinogen sovacivec (TG4001), an HPV-16 cancer vaccine: a randomized phase 2 study in recurrent or metastatic (R/M) anogenital cancers
- Advanced patient-derived lung tumoroids to identify limiting factors for oncolytic virotherapy
H. Le et al.
AACR 2023
Download the poster here
Poster Presentation - PoxSTG, a novel chimeric poxvirus with improved oncolytic potency
P Erbs et al.
AACR 2023
Download the poster here
Poster Presentation - Oncolytic virus TG6002 safety and activity after intrahepatic artery administration in patients with liver-dominant metastatic colorectal cancer
A. Samson et al.
AACR 2023
Download the poster here
Poster Presentation - Feasibility and immunogenicity of adjuvant TG4050, a patient tailored cancer vaccine in head and neck and ovarian cancer
A. Lalane et al.
AACR 2023
Download the poster here
Poster Presentation - A randomized phase II trial of TG4001 plus avelumab versus avelumab alone in recurrent/metastatic (R/M) human papilloma virus (HPV)-16 positive anogenital cancers
C. Le Tourneau et al.
AACR 2023
Download the poster here
Poster Presentation - Selection of an optimal anti-PD-L1 single domain antibody format for the vectorization into oncolytic vaccinia virus and the generation of bispecific immunomodulators
JB. Marchand et al.
AACR 2023
Download the poster here
Poster Presentation - TG6050 an oncolytic vaccinia virus armed with interleukin 12 and anti-CTLA4 antibody induces TME remodeling and strong anti-tumoral responses
JB. Marchand et al.
AACR 2023
Download the poster here
Poster Presentation - Extracellular vesicles (EV): mediators of therapeutic vaccination? In vivo and in vitro characterization of EVs generated after infection of human and murine cells with therapeutic poxviruses
L. Walther et al.
AACR 2023
Download the poster here
Poster Presentation
- Updated data of biodistribution and activity of oncolytic virus TG6002 after intravenous administration in patients with advanced gastrointestinal carcinomas
V. Moreno et al.
ESMO 2022
Download the poster here
Poster Presentation - Phase 1 studies of personalized neoantigen vaccine TG4050 in ovarian carcinoma (OC) and head and heck carcinoma (HNSCC)
JP Delord, et al.
ASCO 2022
Abstract available on the ASCO website – Download the poster here
Poster Presentation - Pseudocowpox virus, a novel vector to enhance the therapeutic efficacy of antitumor vaccination
Rodrigo Nalio Ramos, et al.
Clinical and Translational Immunology, May 8 2022 – Read the article
Publication - Comprehensive preclinical studies of BT-001: an oncolytic vaccinia virus armed with Treg-depleting @CTLA4 and GM-CSF
- Phase I trials of personalized cancer vaccine TG4050 in surgically treated high-risk head and neck squamous cell carcinoma (HNSCC) and relapsing ovarian cancer (OvC) patients
- Vectorized Treg-depleting αCTLA-4 elicits antigen cross-presentation and CD8+ T cell immunity to reject “cold” tumors
Semmrich M, Marchand J, Fend L, et al
Journal for ImmunoTherapy of Cancer
Download the publication here
Publication
- Bioavailability and activity of oncolytic virus TG6002 after intravenous administration in patients with advanced gastrointestinal carcinomas
P. Cassier et al.
ESMO 2021
Download the poster here
Poster Presentation - 3D organoids derived from patients’ lung tumors: a tool for investigating the potential of oncolytic viruses
Hélène Lê et al.
EUROoCS 2021
Download the Poster here
Poster Presentation - Oncolytic virus TG6002 locates to tumors after intravenous infusion and induces tumor-specific expression of a functional pro-drug activating enzyme in patients with advanced gastrointestinal carcinomas
- Immunocompetent cancer-on-chip models to assess immuno-oncology therapy
Tengku Ibrahim Maulana, et al.
Adv Drug Deliv Rev., March 30 2021 – Read the article
Publication - Correlation of HPV16 Gene Status and Gene Expression With Antibody Seropositivity and TIL Status in OPSCC
Adrian von Witzleben, et al.
Front Oncol., January 26 2021 – Read the article
Publication - Safety, biodistribution and viral shedding of oncolytic vaccinia virus TG6002 administered intravenously in healthy beagle dogs
Jérémy Béguin, et al.
Sci Rep., January 26 2021 – Read the article
Publication
- Fluorescent Tagged Vaccinia Virus Genome Allows Rapid and Efficient Measurement of Oncolytic Potential and Discovery of Oncolytic Modulators
Franck Gallardo, et al.
Biomedicines, November 26 2020 – Read the article
Publication - BT-001, an oncolytic vaccinia virus armed with a Treg-depleting human recombinant anti-CTLA4 antibody and GM-CSF to target the tumor microenvironment
M. Semmrich et al.
SITC 2020
Download the poster here
Poster Presentation - TG4001 (Tipapkinogene sovacivec) and avelumab for recurrent/metastatic (R/M) Human Papilloma Virus (HPV)-16+ cancers: clinical efficacy and immunogenicity
C. Le Tourneau et al.
SITC 2020
Download the poster here
Poster Presentation - High Oncolytic Activity of a Double-Deleted Vaccinia Virus Copenhagen Strain against Malignant Pleural Mesothelioma
Tiphaine Delaunay, et al.
Molecular Therapy Oncolytics, September 2020 – Read the article and view videos
Publication - Preclinical Evaluation of the Oncolytic Vaccinia Virus TG6002 by Translational Research on Canine Breast Cancer
Jérémy Béguin, et al.
Molecular Therapy Oncolytics, September 2020 – Read the article
Publication - Safety studies and viral shedding of intramuscular administration of oncolytic vaccinia virus TG6002 in healthy beagle dogs
Jérémy Béguin, et al.
BMC Vet Res., August 25 2020 – Read the article
Publication - Design of an Innovative Model to Improve Anticancer Therapeutic Treatment Based on a Vascularized 3D Organoids Derived from Patients’ Lung Tumors for the Purpose of Precision Medicine
H. Le et al.
EUROoCS 2020
Download the poster here
Poster Presentation - Performance of neoantigen prediction for the design of TG4050, a patient specific neoantigen cancer vaccine
B. Mallone et al.
AACR 2020
Download the poster here
Poster Presentation - BT-001, an oncolytic Vaccinia virus armed with a Treg-depletion-optimized recombinant human anti-CTLA4 antibody and GM-CSF to target the tumor microenvironment
Jean-Baptiste Marchand et al.
AACR 2020
Download the poster here
Poster Presentation - Oncolytic Vaccinia Virus expressing Cytidine Deaminase induces DNA damage and shows potent anti-tumor effects
J. Foloppe et al.
AACR 2020
Download the poster here
Poster Presentation - BT-001, an oncolytic Vaccinia virus armed with a Treg-depletion-optimized recombinant human anti- CTLA4 antibody and GM-CSF to target the tumor microenvironment
Marchand, Semmrich, Fend et al.
Immuno-Oncology summit
Download the poster here
Poster Presentation - Non-clinical and clinical safety of MVA-based immunotherapy products targeting cancer and infectious diseases
Clémentine Spring-Giusti et al.
American College of Toxicology – 40th Annual Meeting
Download the poster here
Poster Presentation - Oncolytic Vaccinia virus contains a potent CD80/CD86 ligand whose deletion confers higher tolerance, and potential synergy with immune arming
Jean-Baptiste Marchand et al.
SITC 2019
Download the poster here
Poster Presentation
- Meta analysis of two phase 1b randomized, double blind, placebo controlled clinical trials of the HBV therapeutic vaccines TG1050 and T101 developed in Europe/Canada or China
Fabien Zoulim et al.
AASLD 2019
Download the poster here
Poster Presentation - Phase Ib/II trial of TG4001 (Tipapkinogene sovacivec), a therapeutic HPV-vaccine, and Avelumab in patients with recurrent/metastatic HPV16 positive cancers
Christophe Le Tourneau et al.
ESMO 2019
Download the poster here
Poster Presentation - The efficacy and safety of Tipapkinogen Sovacivec (TG4001) therapeutic HPV vaccine in cervical intraepithelial neoplasia grades 2 and 3: Randomized controlled phase II trial with 2.5 years of follow-up
Diane M. Harper, et al.
Gynecologic Oncology, April 2019 – Download the article
The publication has been featured in The Lancet Oncology and Medpage Today
Publication - The Enhanced Tumor Specificity of TG6002, an Armed Oncolytic Vaccinia Virus Deleted in Two Genes Involved in Nucleotide Metabolism
Johann Foloppe, et al.
Molecular Therapy Oncolytics, March 2019 – Download the article
Publication
- Investigational treatment combining TG1050, an HBV-specific immunotherapeutic, with direct acting antivirals or immunomodulators, improves sustained antiviral effects and immune responses in HBV-persistent mice
Roland Kratzer, et al.
AASLD, The Liver Meeting 2018, November 2018 – Abstract available on the AASLD website
Download the poster here
Poster PresentationCollaboration between Transgene – Laboratoire de Recherches Biochirurgicales, Université Paris Descartes, Hôpital Européen Georges Pompidou, Paris, France – Université Paris Diderot, Sorbonne Paris Cité, Paris, France – Hôpital Saint-Louis, Assistance Publique-Hôpitaux de Paris (AP-HP), Paris, France – Alnylam Pharmaceuticals, Cambridge, USA – The State Key Laboratory of Anti-Infection Drug Development, HEC Pharma Group, Dong Guan, China
- Safety and Immunogenicity of Single and Multiple Injections of the Therapeutic Vaccine TG1050 in NUC-Suppressed Chronic Hepatitis B (CHB) Patients: Unblinded Analysis of a Double-Blind, Placebo-Controlled Phase 1b Study
Claire Fournier, et al.
AASLD, The Liver Meeting 2018, November 2018 – Abstract available on the AASLD website
Download the poster here
Poster Presentation - myvac™ Viral based vaccine for personalized neoantigen-directed cancer therapy
Christian Ottensmeier, et al.
SITC 2018, November 2018 – Abstract available on the SITC website
Download the poster here
Poster PresentationCollaboration between Transgene – University of Southampton, United Kingdom – La Jolla Institute for allergy and immunology, USA – University of Copenhagen, Denmark
- Pseudocowpox virus (PCPV), a potent viral vector for both antigen-dependent and independent cancer immunotherapy
Karola Rittner, et al.
SITC 2018, November 2018 – Abstract available on the SITC website
Download the poster here
Poster Presentation - Antibody-armed oncolytic Vaccinia virus to block immunosuppressive pathways in the tumor microenvironment
Jean-Baptiste Marchand et al.
SITC 2018, November 2018 – Abstract available on the SITC website
Download the poster here
Poster PresentationCollaboration between Transgene – BioInvent International A.B, Sweden
- Single intravenous preoperative administration of the oncolytic virus Pexa-Vec to prime anti-tumor immunity
Alan Anthoney, et al.
ASCO 2018, June 2018 – Abstract available on the ASCO website
Download the poster here
Poster Presentation - A multi-antigenic MVA vaccine increases efficacy of combination chemotherapy against Mycobacterium tuberculosis
Stephane Leung-Theung-Long, et al.
PLOS One, May 2018 – Download the article
Publication - Pseudocowpox: A next generation viral vector for cancer immunotherapy
Karolina Rittner, et al.
AACR 2018, April 2018 – Abstract available on the AACR 2018 website
Download the poster here
Poster Presentation - TG6002: a novel oncolytic and vectorized gene-prodrug therapy approach to treat glioblastoma
Johann Foloppe, et al.
International Oncolytic Virus Conference, April 2018
Download the poster here
Poster Presentation - TG1050 is well tolerated and induces a strong specific immune response in patients with chronic hepatitis B
Martin F. Sprinzl, et al.
AASLD & Hepatology, October 2017
Download the poster here
Poster Presentation
- Viral based vaccine TG4010 induces broadening of specific immune response and improves outcome in advanced NSCLC
Caroline Tosch, et al.
Journal for ImmunoTherapy of Cancer, 2017, 5:70 – Download the article
Publication - Sequential administration of MVA-based vaccines and PD-1/PD-L1-blocking antibodies confers measurable benefits on tumor growth and survival: preclinical studies with MVA-βGal and MVA-MUC1 (TG4010) in a murine tumor model
Christelle Remy-Ziller, et al.
Human Vaccines & Immunotherapeutics, 2017, 19:0 – Download the article
Publication - A phase Ib trial of JX-594 (Pexa-Vec), a targeted multimechanistic oncolytic vaccinia virus, in combination with low-dose cyclophosphamide in patients with advanced solid tumors
Maud Toulmonde, et al.
ESMO 2017, September 11, 2017, 13:15 – 14:15, Hall 8
Download the poster here
Poster Presentation - Modified Vaccinia virus Ankara-based vaccines in the era of personalized immunotherapy of cancer
K. Bendjama, E. Quéméneur
Human Vaccines and Immunotherapeutics, August 2017 – Read the article
Publication - Immune Checkpoint Blockade, Immunogenic Chemotherapy or IFN-α Blockade Boost the Local and Abscopal Effects of Oncolytic Virotherapy
Laetitia Fend, et al.
Cancer Research, July 2017, DOI: 10.1158/0008-5472.CAN-16-2165 – Download the article
Publication - TG6002: A novel oncolytic and vectorized gene pro-drug therapy approach to treat glioblastoma
Ahmed Idbaih, et al.
ASCO 2017, June 2017 – Download the abstract
Abstract - Local and Abscopal Effects in Oncolytic Virotherapy are boosted by Immune Checkpoint Blockade, Immunogenic Chemotherapy, or IFNAR blockade
Laetitia Fend, et al.
AACR, American Association for cancer Research, April 2017
Download the poster here
Poster Presentation - In situ Biomarker analysis in cancer Immunotherapy: development of quantitative multiplex IHC
Sandrine Cochin, et al.
CLARA, Forum de la recherche en cancérologie, April 2017
Download the poster here
Poster Presentation - Vectorized gene therapy of liver tumors: proof-of-concept of TG4023 (MVA-FCU1) in combination with flucytosine
Faleh Husseini, et al.
Annals of Oncology, February 2017, DOI: https://doi.org/10.1093/annonc/mdw440 – Download the article
PublicationTG4023 is a non-replicative MVA integrating the FCU1 gene that has been inserted in the oncolytic virus TG6002.
- Radiotherapy and MVA-MUC1-IL-2 vaccine act synergistically for inducing specific immunity to MUC-1 tumor antigen
Gilda G. Hillman, et al.
Journal for ImmunoTherapy of Cancer, January 2017 – Download the article
Publication - TG1050, an HBV-targeted immunotherapeutics, efficiently decreases HBV viremia and antigenemia in a preclinical model; a meta-analysis and the determination of the involvement of CD4 and CD8 T cells.
Roland Kratzer, et al.
AASLD & Hepatology, October 2016 – DOI: 10.1002/hep.28800
Download the poster here
Poster Presentation - Vectorization in an oncolytic vaccinia virus of an antibody, a Fab and a scFv against programmed cell death -1 (PD-1) allows their intratumoral delivery and an improved tumor-growth inhibition
Patricia Kleinpeter, et al.
OncoImmunology, October 2016 – Download the article
Publication - Engineering Oncolytic Vaccinia Virus with Improved Cancer Killing Abilities
Johann Foloppe, et al.
10th International Meeting on Replicating Oncolytic Virus Therapeutics, Vancouver, Canada – 1-4 October 2016
Download the poster here
Poster PresentationCollaboration between Transgene – HTS facility IGBMC, Illkirch – France IREBS, Illkirch, France – ICube, Strasbourg, France
- Oncolytic vaccinia virus TG6002 demonstrates potent efficiency in pancreatic tumor alone and in combination with standard chemotherapies
Johann Foloppe, et al.
XXI International Poxvirus, Asfavirus and Iridovirus Conference Le Bischenberg (France) 1-5 July 2016
Download the poster here
Poster Presentation - Evaluation of a novel oncolytic Raccoonpox virus expressing the bifunctional FCU1 suicide gene
Marine Ricordel, et al.
XXI International Poxvirus, Asfavirus and Iridovirus Conference Le Bischenberg (France) 1-5 July 2016
Download the poster here
Poster Presentation - Vectorization in an oncolytic vaccinia virus of an antibody, a Fab and a scFv against programmed cell death-1 (PD-1) allow their intratumoral delivery and an improved tumor growth inhibition
Jean Baptiste Marchand, et al.
XXI International Poxvirus, Asfavirus and Iridovirus Conference Le Bischenberg (France) 1-5 July 2016
Download the poster here
Poster Presentation - Improvement of MVA-based Vaccines by Expression of an Autophagy Inhibitor
Anita Spindler, et al.
XXI International Poxvirus, Asfavirus and Iridovirus Conference Le Bischenberg (France) 1-5 July 2016
Download the poster here
Poster Presentation - A Phase 3 Randomized, Open-Label Study Comparing Pexa-Vec (Vaccinia GM-CSF / Thymidine Kinase-Deactivated Virus) Followed by Sorafenib Versus Sorafenib in Patients with Advanced Hepatocellular Carcinoma (HCC) Without Prior Systemic Therapy
Ghassan K. Abou-Alfa, et al.
ASCO Annual Meeting 2016, June 3-7, 2016, Chicago Illinois
Download the poster here
Poster Presentation - Vectorization in an oncolytic vaccinia virus of an antibody, a Fab and a scFv against programmed cell death -1 (PD-1) allow their intratumoral delivery and an improved tumor-growth inhibition
Jean Baptiste Marchand, et al.
AACR Annual Meeting 2016, April 16-20, 2016, E.N. MorialConvention Center, New Orleans, Louisiana
Download the poster here
Poster Presentation
- Personalized vaccine TG4050 induces polyepitopic immune responses against private neoantigens in resected HPV negative head and neck cancers
A. Lalanne, et al.
AACR 2024
Abstract available on the AACR website – Download the poster
Poster Presentation - Phase Ib/II trial of tipapkinogene sovacivec (TG4001), a therapeutic human papillomavirus 16-vaccine, in combination with avelumab in patients with advanced human papillomavirus 16-positive cancers
C. Le Tourneau, et al.
European Journal of Cancer, July 2023 (191)
Access the article here
Publication - Safety and Immunogenicity of TG4050; a personalized cancer vaccine in head and neck carcinoma
C. Ottensmeier, et al.
ASCO 2023
Abstract available on the ASCO website – Download the abstract and the poster
Poster Presentation - Immunogenicity and clinical activity of Tipapkinogen sovacivec (TG4001), an HPV-16 cancer vaccine: a randomized phase 2 study in recurrent or metastatic (R/M) anogenital cancers
- Advanced patient-derived lung tumoroids to identify limiting factors for oncolytic virotherapy
H. Le et al.
AACR 2023
Download the poster here
Poster Presentation - PoxSTG, a novel chimeric poxvirus with improved oncolytic potency
P Erbs et al.
AACR 2023
Download the poster here
Poster Presentation - Oncolytic virus TG6002 safety and activity after intrahepatic artery administration in patients with liver-dominant metastatic colorectal cancer
A. Samson et al.
AACR 2023
Download the poster here
Poster Presentation - Feasibility and immunogenicity of adjuvant TG4050, a patient tailored cancer vaccine in head and neck and ovarian cancer
A. Lalane et al.
AACR 2023
Download the poster here
Poster Presentation - A randomized phase II trial of TG4001 plus avelumab versus avelumab alone in recurrent/metastatic (R/M) human papilloma virus (HPV)-16 positive anogenital cancers
C. Le Tourneau et al.
AACR 2023
Download the poster here
Poster Presentation - Selection of an optimal anti-PD-L1 single domain antibody format for the vectorization into oncolytic vaccinia virus and the generation of bispecific immunomodulators
JB. Marchand et al.
AACR 2023
Download the poster here
Poster Presentation - TG6050 an oncolytic vaccinia virus armed with interleukin 12 and anti-CTLA4 antibody induces TME remodeling and strong anti-tumoral responses
JB. Marchand et al.
AACR 2023
Download the poster here
Poster Presentation - Extracellular vesicles (EV): mediators of therapeutic vaccination? In vivo and in vitro characterization of EVs generated after infection of human and murine cells with therapeutic poxviruses
L. Walther et al.
AACR 2023
Download the poster here
Poster Presentation - Updated data of biodistribution and activity of oncolytic virus TG6002 after intravenous administration in patients with advanced gastrointestinal carcinomas
V. Moreno et al.
ESMO 2022
Download the poster here
Poster Presentation - Phase 1 studies of personalized neoantigen vaccine TG4050 in ovarian carcinoma (OC) and head and heck carcinoma (HNSCC)
JP Delord, et al.
ASCO 2022
Abstract available on the ASCO website – Download the poster here
Poster Presentation - Pseudocowpox virus, a novel vector to enhance the therapeutic efficacy of antitumor vaccination
Rodrigo Nalio Ramos, et al.
Clinical and Translational Immunology, May 8 2022 – Read the article
Publication - Comprehensive preclinical studies of BT-001: an oncolytic vaccinia virus armed with Treg-depleting @CTLA4 and GM-CSF
- Phase I trials of personalized cancer vaccine TG4050 in surgically treated high-risk head and neck squamous cell carcinoma (HNSCC) and relapsing ovarian cancer (OvC) patients
- Vectorized Treg-depleting αCTLA-4 elicits antigen cross-presentation and CD8+ T cell immunity to reject “cold” tumors
Semmrich M, Marchand J, Fend L, et al
Journal for ImmunoTherapy of Cancer
Download the publication here
Publication - Bioavailability and activity of oncolytic virus TG6002 after intravenous administration in patients with advanced gastrointestinal carcinomas
P. Cassier et al.
ESMO 2021
Download the poster here
Poster Presentation - 3D organoids derived from patients’ lung tumors: a tool for investigating the potential of oncolytic viruses
Hélène Lê et al.
EUROoCS 2021
Download the Poster here
Poster Presentation - Oncolytic virus TG6002 locates to tumors after intravenous infusion and induces tumor-specific expression of a functional pro-drug activating enzyme in patients with advanced gastrointestinal carcinomas
- Immunocompetent cancer-on-chip models to assess immuno-oncology therapy
Tengku Ibrahim Maulana, et al.
Adv Drug Deliv Rev., March 30 2021 – Read the article
Publication - Correlation of HPV16 Gene Status and Gene Expression With Antibody Seropositivity and TIL Status in OPSCC
Adrian von Witzleben, et al.
Front Oncol., January 26 2021 – Read the article
Publication - Safety, biodistribution and viral shedding of oncolytic vaccinia virus TG6002 administered intravenously in healthy beagle dogs
Jérémy Béguin, et al.
Sci Rep., January 26 2021 – Read the article
Publication - Fluorescent Tagged Vaccinia Virus Genome Allows Rapid and Efficient Measurement of Oncolytic Potential and Discovery of Oncolytic Modulators
Franck Gallardo, et al.
Biomedicines, November 26 2020 – Read the article
Publication - BT-001, an oncolytic vaccinia virus armed with a Treg-depleting human recombinant anti-CTLA4 antibody and GM-CSF to target the tumor microenvironment
M. Semmrich et al.
SITC 2020
Download the poster here
Poster Presentation - TG4001 (Tipapkinogene sovacivec) and avelumab for recurrent/metastatic (R/M) Human Papilloma Virus (HPV)-16+ cancers: clinical efficacy and immunogenicity
C. Le Tourneau et al.
SITC 2020
Download the poster here
Poster Presentation - High Oncolytic Activity of a Double-Deleted Vaccinia Virus Copenhagen Strain against Malignant Pleural Mesothelioma
Tiphaine Delaunay, et al.
Molecular Therapy Oncolytics, September 2020 – Read the article and view videos
Publication - Preclinical Evaluation of the Oncolytic Vaccinia Virus TG6002 by Translational Research on Canine Breast Cancer
Jérémy Béguin, et al.
Molecular Therapy Oncolytics, September 2020 – Read the article
Publication - Safety studies and viral shedding of intramuscular administration of oncolytic vaccinia virus TG6002 in healthy beagle dogs
Jérémy Béguin, et al.
BMC Vet Res., August 25 2020 – Read the article
Publication - Design of an Innovative Model to Improve Anticancer Therapeutic Treatment Based on a Vascularized 3D Organoids Derived from Patients’ Lung Tumors for the Purpose of Precision Medicine
H. Le et al.
EUROoCS 2020
Download the poster here
Poster Presentation - Performance of neoantigen prediction for the design of TG4050, a patient specific neoantigen cancer vaccine
B. Mallone et al.
AACR 2020
Download the poster here
Poster Presentation - BT-001, an oncolytic Vaccinia virus armed with a Treg-depletion-optimized recombinant human anti-CTLA4 antibody and GM-CSF to target the tumor microenvironment
Jean-Baptiste Marchand et al.
AACR 2020
Download the poster here
Poster Presentation - Oncolytic Vaccinia Virus expressing Cytidine Deaminase induces DNA damage and shows potent anti-tumor effects
J. Foloppe et al.
AACR 2020
Download the poster here
Poster Presentation - BT-001, an oncolytic Vaccinia virus armed with a Treg-depletion-optimized recombinant human anti- CTLA4 antibody and GM-CSF to target the tumor microenvironment
Marchand, Semmrich, Fend et al.
Immuno-Oncology summit
Download the poster here
Poster Presentation - Non-clinical and clinical safety of MVA-based immunotherapy products targeting cancer and infectious diseases
Clémentine Spring-Giusti et al.
American College of Toxicology – 40th Annual Meeting
Download the poster here
Poster Presentation - Meta analysis of two phase 1b randomized, double blind, placebo controlled clinical trials of the HBV therapeutic vaccines TG1050 and T101 developed in Europe/Canada or China
Fabien Zoulim et al.
AASLD 2019
Download the poster here
Poster Presentation - Oncolytic Vaccinia virus contains a potent CD80/CD86 ligand whose deletion confers higher tolerance, and potential synergy with immune arming
Jean-Baptiste Marchand et al.
SITC 2019
Download the poster here
Poster Presentation - Phase Ib/II trial of TG4001 (Tipapkinogene sovacivec), a therapeutic HPV-vaccine, and Avelumab in patients with recurrent/metastatic HPV16 positive cancers
Christophe Le Tourneau et al.
ESMO 2019
Download the poster here
Poster Presentation - The efficacy and safety of Tipapkinogen Sovacivec (TG4001) therapeutic HPV vaccine in cervical intraepithelial neoplasia grades 2 and 3: Randomized controlled phase II trial with 2.5 years of follow-up
Diane M. Harper, et al.
Gynecologic Oncology, April 2019 – Download the article
The publication has been featured in The Lancet Oncology and Medpage Today
Publication - The Enhanced Tumor Specificity of TG6002, an Armed Oncolytic Vaccinia Virus Deleted in Two Genes Involved in Nucleotide Metabolism
Johann Foloppe, et al.
Molecular Therapy Oncolytics, March 2019 – Download the article
Publication - Investigational treatment combining TG1050, an HBV-specific immunotherapeutic, with direct acting antivirals or immunomodulators, improves sustained antiviral effects and immune responses in HBV-persistent mice
Roland Kratzer, et al.
AASLD, The Liver Meeting 2018, November 2018 – Abstract available on the AASLD website
Download the poster here
Poster PresentationCollaboration between Transgene – Laboratoire de Recherches Biochirurgicales, Université Paris Descartes, Hôpital Européen Georges Pompidou, Paris, France – Université Paris Diderot, Sorbonne Paris Cité, Paris, France – Hôpital Saint-Louis, Assistance Publique-Hôpitaux de Paris (AP-HP), Paris, France – Alnylam Pharmaceuticals, Cambridge, USA – The State Key Laboratory of Anti-Infection Drug Development, HEC Pharma Group, Dong Guan, China
- Safety and Immunogenicity of Single and Multiple Injections of the Therapeutic Vaccine TG1050 in NUC-Suppressed Chronic Hepatitis B (CHB) Patients: Unblinded Analysis of a Double-Blind, Placebo-Controlled Phase 1b Study
Claire Fournier, et al.
AASLD, The Liver Meeting 2018, November 2018 – Abstract available on the AASLD website
Download the poster here
Poster Presentation - myvac™ Viral based vaccine for personalized neoantigen-directed cancer therapy
Christian Ottensmeier, et al.
SITC 2018, November 2018 – Abstract available on the SITC website
Download the poster here
Poster PresentationCollaboration between Transgene – University of Southampton, United Kingdom – La Jolla Institute for allergy and immunology, USA – University of Copenhagen, Denmark
- Pseudocowpox virus (PCPV), a potent viral vector for both antigen-dependent and independent cancer immunotherapy
Karola Rittner, et al.
SITC 2018, November 2018 – Abstract available on the SITC website
Download the poster here
Poster Presentation - Antibody-armed oncolytic Vaccinia virus to block immunosuppressive pathways in the tumor microenvironment
Jean-Baptiste Marchand et al.
SITC 2018, November 2018 – Abstract available on the SITC website
Download the poster here
Poster PresentationCollaboration between Transgene – BioInvent International A.B, Sweden
- Single intravenous preoperative administration of the oncolytic virus Pexa-Vec to prime anti-tumor immunity
Alan Anthoney, et al.
ASCO 2018, June 2018 – Abstract available on the ASCO website
Download the poster here
Poster Presentation - A multi-antigenic MVA vaccine increases efficacy of combination chemotherapy against Mycobacterium tuberculosis
Stephane Leung-Theung-Long, et al.
PLOS One, May 2018 – Download the article
Publication - Pseudocowpox: A next generation viral vector for cancer immunotherapy
Karolina Rittner, et al.
AACR 2018, April 2018 – Abstract available on the AACR 2018 website
Download the poster here
Poster Presentation - TG6002: a novel oncolytic and vectorized gene-prodrug therapy approach to treat glioblastoma
Johann Foloppe, et al.
International Oncolytic Virus Conference, April 2018
Download the poster here
Poster Presentation - TG1050 is well tolerated and induces a strong specific immune response in patients with chronic hepatitis B
Martin F. Sprinzl, et al.
AASLD & Hepatology, October 2017
Download the poster here
Poster Presentation - Viral based vaccine TG4010 induces broadening of specific immune response and improves outcome in advanced NSCLC
Caroline Tosch, et al.
Journal for ImmunoTherapy of Cancer, 2017, 5:70 – Download the article
Publication - Sequential administration of MVA-based vaccines and PD-1/PD-L1-blocking antibodies confers measurable benefits on tumor growth and survival: preclinical studies with MVA-βGal and MVA-MUC1 (TG4010) in a murine tumor model
Christelle Remy-Ziller, et al.
Human Vaccines & Immunotherapeutics, 2017, 19:0 – Download the article
Publication - A phase Ib trial of JX-594 (Pexa-Vec), a targeted multimechanistic oncolytic vaccinia virus, in combination with low-dose cyclophosphamide in patients with advanced solid tumors
Maud Toulmonde, et al.
ESMO 2017, September 11, 2017, 13:15 – 14:15, Hall 8
Download the poster here
Poster Presentation - Modified Vaccinia virus Ankara-based vaccines in the era of personalized immunotherapy of cancer
K. Bendjama, E. Quéméneur
Human Vaccines and Immunotherapeutics, August 2017 – Read the article
Publication - Immune Checkpoint Blockade, Immunogenic Chemotherapy or IFN-α Blockade Boost the Local and Abscopal Effects of Oncolytic Virotherapy
Laetitia Fend, et al.
Cancer Research, July 2017, DOI: 10.1158/0008-5472.CAN-16-2165 – Download the article
Publication - TG6002: A novel oncolytic and vectorized gene pro-drug therapy approach to treat glioblastoma
Ahmed Idbaih, et al.
ASCO 2017, June 2017 – Download the abstract
Abstract - Local and Abscopal Effects in Oncolytic Virotherapy are boosted by Immune Checkpoint Blockade, Immunogenic Chemotherapy, or IFNAR blockade
Laetitia Fend, et al.
AACR, American Association for cancer Research, April 2017
Download the poster here
Poster Presentation - In situ Biomarker analysis in cancer Immunotherapy: development of quantitative multiplex IHC
Sandrine Cochin, et al.
CLARA, Forum de la recherche en cancérologie, April 2017
Download the poster here
Poster Presentation - Vectorized gene therapy of liver tumors: proof-of-concept of TG4023 (MVA-FCU1) in combination with flucytosine
Faleh Husseini, et al.
Annals of Oncology, February 2017, DOI: https://doi.org/10.1093/annonc/mdw440 – Download the article
PublicationTG4023 is a non-replicative MVA integrating the FCU1 gene that has been inserted in the oncolytic virus TG6002.
- Radiotherapy and MVA-MUC1-IL-2 vaccine act synergistically for inducing specific immunity to MUC-1 tumor antigen
Gilda G. Hillman, et al.
Journal for ImmunoTherapy of Cancer, January 2017 – Download the article
Publication - TG1050, an HBV-targeted immunotherapeutics, efficiently decreases HBV viremia and antigenemia in a preclinical model; a meta-analysis and the determination of the involvement of CD4 and CD8 T cells.
Roland Kratzer, et al.
AASLD & Hepatology, October 2016 – DOI: 10.1002/hep.28800
Download the poster here
Poster Presentation - Vectorization in an oncolytic vaccinia virus of an antibody, a Fab and a scFv against programmed cell death -1 (PD-1) allows their intratumoral delivery and an improved tumor-growth inhibition
Patricia Kleinpeter, et al.
OncoImmunology, October 2016 – Download the article
Publication - Engineering Oncolytic Vaccinia Virus with Improved Cancer Killing Abilities
Johann Foloppe, et al.
10th International Meeting on Replicating Oncolytic Virus Therapeutics, Vancouver, Canada – 1-4 October 2016
Download the poster here
Poster PresentationCollaboration between Transgene – HTS facility IGBMC, Illkirch – France IREBS, Illkirch, France – ICube, Strasbourg, France
- Oncolytic vaccinia virus TG6002 demonstrates potent efficiency in pancreatic tumor alone and in combination with standard chemotherapies
Johann Foloppe, et al.
XXI International Poxvirus, Asfavirus and Iridovirus Conference Le Bischenberg (France) 1-5 July 2016
Download the poster here
Poster Presentation - Evaluation of a novel oncolytic Raccoonpox virus expressing the bifunctional FCU1 suicide gene
Marine Ricordel, et al.
XXI International Poxvirus, Asfavirus and Iridovirus Conference Le Bischenberg (France) 1-5 July 2016
Download the poster here
Poster Presentation - Vectorization in an oncolytic vaccinia virus of an antibody, a Fab and a scFv against programmed cell death-1 (PD-1) allow their intratumoral delivery and an improved tumor growth inhibition
Jean Baptiste Marchand, et al.
XXI International Poxvirus, Asfavirus and Iridovirus Conference Le Bischenberg (France) 1-5 July 2016
Download the poster here
Poster Presentation - Improvement of MVA-based Vaccines by Expression of an Autophagy Inhibitor
Anita Spindler, et al.
XXI International Poxvirus, Asfavirus and Iridovirus Conference Le Bischenberg (France) 1-5 July 2016
Download the poster here
Poster Presentation - A Phase 3 Randomized, Open-Label Study Comparing Pexa-Vec (Vaccinia GM-CSF / Thymidine Kinase-Deactivated Virus) Followed by Sorafenib Versus Sorafenib in Patients with Advanced Hepatocellular Carcinoma (HCC) Without Prior Systemic Therapy
Ghassan K. Abou-Alfa, et al.
ASCO Annual Meeting 2016, June 3-7, 2016, Chicago Illinois
Download the poster here
Poster Presentation - Vectorization in an oncolytic vaccinia virus of an antibody, a Fab and a scFv against programmed cell death -1 (PD-1) allow their intratumoral delivery and an improved tumor-growth inhibition
Jean Baptiste Marchand, et al.
AACR Annual Meeting 2016, April 16-20, 2016, E.N. MorialConvention Center, New Orleans, Louisiana
Download the poster here
Poster Presentation - TG4010 immunotherapy and first-line chemotherapy for advanced non-small-cell lung cancer (TIME): results from the phase 2b part of a randomised, double-blind, placebo-controlled, phase 2b/3 trial
Elisabeth Quoix, et al.
The Lancet Oncology, December 2015, 17: 212–23 – Download the article
Publication - A Novel MVA-Based Multiphasic Vaccine for Prevention or Treatment of Tuberculosis Induces Broad and Multifunctional Cell-Mediated Immunity in Mice and Primates
Stephane Leung-Theung-Long, et al.
PLOS One, November 24, 2015 DOI: 10.1371/journal.pone.0143552 – Download the article
Publication - TG4010 immunotherapy plus chemotherapy as first-line treatment of advanced NSCLC: Phase 2b Results of the TIME trial
John Nemunaitis, et al.
SITC 2015, November 2015 – Abstract available on the SITC website
Download the poster here
Poster Presentation - Recognition of core-derived epitopes from a novel HBV-targeted immunotherapeutic by T-cells from patients infected by different viral genotypes.
Ophelie Godon, et al.
Vaccine. 2015 Aug 26;33(36):4548-53 – Download the article
Publication - TG4010 Immunotherapy plus Chemotherapy as First Line Treatment of Advanced NSCLC: Phase 2b Results.
Elisabeth Quoix, et al.
16th World Conference on Lung Cancer. September 2015, Denver, Colorado
Download the poster here
Poster Presentation - Results of the Phase 2B Part of Time Study Evaluating TG4010 Immunotherapy in Stage IV Non-Small Cell Lung Cancer (NSCLC) Patients Receiving First-Line Chemotherapy
Elisabeth Quoix, et al.
ASCO Annual Meeting 2015 – May 29-June 2, 2015 – Chicago, Illinois
Download the poster here
Poster Presentation - TG1050, a Novel Immunotherapeutic to Treat Chronic Hepatitis B, can Control HBsAg and Provoke HBsAg Seroconversion in HBV-Persistent Mouse Models
Karine Lélu, et al.
Journal of Hepatology, April 2015, Volume 62, Supplement 2, Page S205 – Download the article
Publication - TG1050, a Novel Immunotherapeutic to Treat Chronic Hepatitis B, can Control HBsAg and Provoke HBsAg Seroconversion in HBV-Persistent Mouse Models
Karine Lélu, et al.
EASL Liver Congress 2015, Vienna-23th April 2015
Download the poster here
Poster Presentation - Immune checkpoint inhibitors enhance benefits of modified vaccinia virus Ankara to improve survival in preclinical models of cancer
Karola Rittner, et al.
AACR Annual Meeting, Philadelphia, PA, USA, 18-22 April 2015, Abst. 2497
Download the posterhere
Poster Presentation - The MVA viral platform for the treatment of cancer and chronic infectious diseases: Clinical experience from four randomized controlled phase II studies
Jean-Marc Limacher, et al.
AACR Annual Meeting, Philadelphia, PA, USA, 18-22 April 2015, Abst. 2498.
Download the poster here
Poster Presentation - Viral hepatitis: HBV cure—can we pin our hopes on immunotherapy ?
Hung-Chih Yang, et al.
Nature Reviews Gastroenterology & Hepatology (2015) doi:10.1038/nrgastro.2015.8 – Download the article
Publication - TG1050, an immunotherapeutic to treat chronic hepatitis B, induces robust T cells and exerts an antiviral effect in HBV-persistent mice.
Martin P, Dubois, et al.
Gut. 2014 Nov 26, doi: 10.1136/gutjnl-2014-308041 – Download the article
Publication - TG4010 Immunotherapy Combined with First-line Therapy in Advanced Non- Small Cell Lung Cancer (NSCLC). Phase 2b Results of the TIME Study
Elisabeth Quoix, et al.
Journal for Immunotherapy of Cancer, 2014, 2 (suppl. 3), O12 – Download the article
Publication - TIME: A Phase 2b/3 Evaluating TG4010 in Combination with First-line Therapy in Advanced Non-Small Cell Lung Cancer (NSCLC). Phase 2b results.
Elisabeth Quoix, et al.
ESMO 2014 Congress, Madrid, Spain, 26-30 September 2014, Abst. 5152
Download the poster here
Poster Presentation - Efficacy of immunotherapy with TG4040, Peg-interferon, and ribavirin in A phase 2 study of patients with chronic HCV infection.
Adrian Di Bisceglie, et al.
Gastroenterology, 2014; Mar 18 – Download the article
Publication - Comparative analysis of immunization schedules using a novel adenovirus – based immunotherapeutic targeting hepatitis B in naïve and tolerant mouse models.
Houda Boukhebza, et al.
Vaccine. 2014, 32(26):3256-63. – Download the article
Publication - Combination of the oncolytic vaccinia virus TG6002 with conventional chemotherapeutic agents in human tumor models resistant to viral oncolysis.
Johann Foloppe, et al.
8th International Conference on Oncolytic Virus Therapeutics. 10-13 April 2014, Oxford, United Kingdom, Abst. 64
Download the poster here
Poster Presentation - Immunological characterization of a modified vaccinia virus Ankara vector expressing the human papillomavirus 16 E1 protein.
Christelle Remy-Ziller, et al.
Clinical and vaccine immunology. 2014; 21(2): 147-155 – Download the article
Publication - Immunotherapy for non – small – cell lung cancer: current approaches.
Elisabeth Quoix, et al.
Current Respiratory Care Reports, 2014; 3 (1): 19-25 – Download the article
Publication - Preclinical evaluation of MVA-MUC1-IL2 in combination with chemotherapy in murine models.
Micaël De Meyer, et al.
Journal for Immunotherapy of Cancer, 2013 – Download the article
Publication - TG1050, A viral-vector based immunotherapeutic designed to treat chronic hepatitis B induces immune responses similar to those display by HBV resolving patients and has an early antiviral effects in a HBV tolerant model.
Perrine Martin, et al.
Hepatology, 2013, (58) S1, 222A–225A – Download the article
Publication - Pre-clinical proof-of-concept studies exploring schedules of administration of an adenovirus-based HBV immunotherapeutic show wide potential for induction of robust and long-lasting T-cell responses.
Houda Boukhebza, et al.
Journal of Hepatology, 2013, (58), Supplement 1, S161 – Download the article
Publication - 130 – A multivalent adenovirus-based immunotherapeutic for treatment of chronic hepatitis B induces broad, robust and polyfunctional T cells in naive and HBV tolerant mice.
Perrine Martin, et al.
Journal of Hepatology, 2013, (58), Supplement 1, S57–S58. – Download the article
Publication - Phase II trial of Pexa-Vec (pexastimogene devacirepvec; JX-594), an oncolytic and immunotherapeutic vaccinia virus, followed by sorafenib in patients with advanced hepatocellular carcinoma (HCC)
J. Heo, C. Breitbach, M. Cho, T.H. Hwang, C.W. Kim, U.B. Jeon, H.Y. Woo, K.T. Yoon, J.W. Lee, J. Burke, T. Hickman, K. Dubois, L. Longpre, R. Patt, D.H. Kirn
Journal of clinical Oncology, 2013, 31, (suppl; abstr 4122)
[Publication] - Phase Ib dose-escalation study of Pexa-Vec (pexastimogene devacirepvec; JX-594), an oncolytic and immunotherapeutic vaccinia virus, administered by intravenous (IV) infusions in patients with metastatic colorectal carcinoma (mCRC)
J. Lee J, S.Y. Park, J. Burke, H.Y. Lim, J. Lee, W.K. Kang, J.O. Park, A. Pelusio, C. Breitbach, D.H. Kirn
Journal of clinical Oncology, 2013, 31, (suppl; abstr 3608)
[Publication] - Oncolytic and immunotherapeutic vaccinia induces antibody-mediated complement-dependent cancer cell lysis in humans
Mi Kyung Kim, et al.
Science Translational Medicine. 2013 May 15;5(185):185ra63 – Download the article
Publication - Randomized dose-finding clinical trial of oncolytic immunotherapeutic vaccinia JX-594 in liver cancer
Jeong Heo, et al.
Nature Medicine, 2013 (3):329-36. doi: 10.1038/nm.3089. Epub 2013 Feb 10. – Download the article
Publication - Therapeutic cancer vaccines in the treatment of non-small cell lung cancer
Jean-Marc Limacher, et al.
Expert Review of Vaccines, 2013; 12(3): 263-270 – Download the article
Publication
Sorted by product
- Personalized vaccine TG4050 induces polyepitopic immune responses against private neoantigens in resected HPV negative head and neck cancers
A. Lalanne, et al.
AACR 2024
Abstract available on the AACR website – Download the poster
Poster Presentation - Safety and Immunogenicity of TG4050; a personalized cancer vaccine in head and neck carcinoma
C. Ottensmeier, et al.
ASCO 2023
Abstract available on the ASCO website – Download the abstract and the poster
Poster Presentation - Feasibility and immunogenicity of adjuvant TG4050, a patient tailored cancer vaccine in head and neck and ovarian cancer
A. Lalane et al.
AACR 2023
Download the poster here
Poster Presentation - Phase 1 studies of personalized neoantigen vaccine TG4050 in ovarian carcinoma (OC) and head and heck carcinoma (HNSCC)
JP Delord, et al.
ASCO 2022
Abstract available on the ASCO website – Download the poster here
Poster Presentation - Phase I trials of personalized cancer vaccine TG4050 in surgically treated high-risk head and neck squamous cell carcinoma (HNSCC) and relapsing ovarian cancer (OvC) patients
- Performance of neoantigen prediction for the design of TG4050, a patient specific neoantigen cancer vaccine
B. Mallone et al.
AACR 2020
Download the poster here
Poster Presentation - Modified Vaccinia virus Ankara-based vaccines in the era of personalized immunotherapy of cancer
K. Bendjama, E. Quéméneur
Human Vaccines and Immunotherapeutics, August 2017 – Read the article
Publication
- Personalized vaccine TG4050 induces polyepitopic immune responses against private neoantigens in resected HPV negative head and neck cancers
A. Lalanne, et al.
AACR 2024
Abstract available on the AACR website – Download the poster
Poster Presentation - Safety and Immunogenicity of TG4050; a personalized cancer vaccine in head and neck carcinoma
C. Ottensmeier, et al.
ASCO 2023
Abstract available on the ASCO website – Download the abstract and the poster
Poster Presentation - Feasibility and immunogenicity of adjuvant TG4050, a patient tailored cancer vaccine in head and neck and ovarian cancer
A. Lalane et al.
AACR 2023
Download the poster here
Poster Presentation - Phase 1 studies of personalized neoantigen vaccine TG4050 in ovarian carcinoma (OC) and head and heck carcinoma (HNSCC)
JP Delord, et al.
ASCO 2022
Abstract available on the ASCO website – Download the poster here
Poster Presentation - Phase I trials of personalized cancer vaccine TG4050 in surgically treated high-risk head and neck squamous cell carcinoma (HNSCC) and relapsing ovarian cancer (OvC) patients
- Performance of neoantigen prediction for the design of TG4050, a patient specific neoantigen cancer vaccine
B. Mallone et al.
AACR 2020
Download the poster here
Poster Presentation - myvac™ Viral based vaccine for personalized neoantigen-directed cancer therapy
Christian Ottensmeier, et al.
SITC 2018, November 2018 – Abstract available on the SITC website
Download the poster here
Poster PresentationCollaboration between Transgene – University of Southampton, United Kingdom – La Jolla Institute for allergy and immunology, USA – University of Copenhagen, Denmark
- Modified Vaccinia virus Ankara-based vaccines in the era of personalized immunotherapy of cancer
K. Bendjama, E. Quéméneur
Human Vaccines and Immunotherapeutics, August 2017 – Read the article
Publication
- Phase Ib/II trial of tipapkinogene sovacivec (TG4001), a therapeutic human papillomavirus 16-vaccine, in combination with avelumab in patients with advanced human papillomavirus 16-positive cancers
C. Le Tourneau, et al.
European Journal of Cancer, July 2023 (191)
Access the article here
Publication - Immunogenicity and clinical activity of Tipapkinogen sovacivec (TG4001), an HPV-16 cancer vaccine: a randomized phase 2 study in recurrent or metastatic (R/M) anogenital cancers
- A randomized phase II trial of TG4001 plus avelumab versus avelumab alone in recurrent/metastatic (R/M) human papilloma virus (HPV)-16 positive anogenital cancers
C. Le Tourneau et al.
AACR 2023
Download the poster here
Poster Presentation - Correlation of HPV16 Gene Status and Gene Expression With Antibody Seropositivity and TIL Status in OPSCC
Adrian von Witzleben, et al.
Front Oncol., January 26 2021 – Read the article
Publication - TG4001 (Tipapkinogene sovacivec) and avelumab for recurrent/metastatic (R/M) Human Papilloma Virus (HPV)-16+ cancers: clinical efficacy and immunogenicity
C. Le Tourneau et al.
SITC 2020
Download the poster here
Poster Presentation - Phase Ib/II trial of TG4001 (Tipapkinogene sovacivec), a therapeutic HPV-vaccine, and Avelumab in patients with recurrent/metastatic HPV16 positive cancers
Christophe Le Tourneau et al.
ESMO 2019
Download the poster here
Poster Presentation - The efficacy and safety of Tipapkinogen Sovacivec (TG4001) therapeutic HPV vaccine in cervical intraepithelial neoplasia grades 2 and 3: Randomized controlled phase II trial with 2.5 years of follow-up
Diane M. Harper, et al.
Gynecologic Oncology, April 2019 – Download the article
The publication has been featured in The Lancet Oncology and Medpage Today
Publication - Immunological characterization of a modified vaccinia virus Ankara vector expressing the human papillomavirus 16 E1 protein.
Christelle Remy-Ziller, et al.
Clinical and vaccine immunology. 2014; 21(2): 147-155 – Download the article
Publication
- Advanced patient-derived lung tumoroids to identify limiting factors for oncolytic virotherapy
H. Le et al.
AACR 2023
Download the poster here
Poster Presentation - PoxSTG, a novel chimeric poxvirus with improved oncolytic potency
P Erbs et al.
AACR 2023
Download the poster here
Poster Presentation - Selection of an optimal anti-PD-L1 single domain antibody format for the vectorization into oncolytic vaccinia virus and the generation of bispecific immunomodulators
JB. Marchand et al.
AACR 2023
Download the poster here
Poster Presentation - TG6050 an oncolytic vaccinia virus armed with interleukin 12 and anti-CTLA4 antibody induces TME remodeling and strong anti-tumoral responses
JB. Marchand et al.
AACR 2023
Download the poster here
Poster Presentation - Comprehensive preclinical studies of BT-001: an oncolytic vaccinia virus armed with Treg-depleting @CTLA4 and GM-CSF
- Vectorized Treg-depleting αCTLA-4 elicits antigen cross-presentation and CD8+ T cell immunity to reject “cold” tumors
Semmrich M, Marchand J, Fend L, et al
Journal for ImmunoTherapy of Cancer
Download the publication here
Publication - 3D organoids derived from patients’ lung tumors: a tool for investigating the potential of oncolytic viruses
Hélène Lê et al.
EUROoCS 2021
Download the Poster here
Poster Presentation - Oncolytic virus TG6002 locates to tumors after intravenous infusion and induces tumor-specific expression of a functional pro-drug activating enzyme in patients with advanced gastrointestinal carcinomas
- Fluorescent Tagged Vaccinia Virus Genome Allows Rapid and Efficient Measurement of Oncolytic Potential and Discovery of Oncolytic Modulators
Franck Gallardo, et al.
Biomedicines, November 26 2020 – Read the article
Publication - BT-001, an oncolytic vaccinia virus armed with a Treg-depleting human recombinant anti-CTLA4 antibody and GM-CSF to target the tumor microenvironment
M. Semmrich et al.
SITC 2020
Download the poster here
Poster Presentation - High Oncolytic Activity of a Double-Deleted Vaccinia Virus Copenhagen Strain against Malignant Pleural Mesothelioma
Tiphaine Delaunay, et al.
Molecular Therapy Oncolytics, September 2020 – Read the article and view videos
Publication - BT-001, an oncolytic Vaccinia virus armed with a Treg-depletion-optimized recombinant human anti-CTLA4 antibody and GM-CSF to target the tumor microenvironment
Jean-Baptiste Marchand et al.
AACR 2020
Download the poster here
Poster Presentation - Oncolytic Vaccinia Virus expressing Cytidine Deaminase induces DNA damage and shows potent anti-tumor effects
J. Foloppe et al.
AACR 2020
Download the poster here
Poster Presentation - BT-001, an oncolytic Vaccinia virus armed with a Treg-depletion-optimized recombinant human anti- CTLA4 antibody and GM-CSF to target the tumor microenvironment
Marchand, Semmrich, Fend et al.
Immuno-Oncology summit
Download the poster here
Poster Presentation - Oncolytic Vaccinia virus contains a potent CD80/CD86 ligand whose deletion confers higher tolerance, and potential synergy with immune arming
Jean-Baptiste Marchand et al.
SITC 2019
Download the poster here
Poster Presentation - Antibody-armed oncolytic Vaccinia virus to block immunosuppressive pathways in the tumor microenvironment
Jean-Baptiste Marchand et al.
SITC 2018, November 2018 – Abstract available on the SITC website
Download the poster here
Poster PresentationCollaboration between Transgene – BioInvent International A.B, Sweden
- Vectorization in an oncolytic vaccinia virus of an antibody, a Fab and a scFv against programmed cell death-1 (PD-1) allow their intratumoral delivery and an improved tumor growth inhibition
Jean Baptiste Marchand, et al.
XXI International Poxvirus, Asfavirus and Iridovirus Conference Le Bischenberg (France) 1-5 July 2016
Download the poster here
Poster Presentation
- Comprehensive preclinical studies of BT-001: an oncolytic vaccinia virus armed with Treg-depleting @CTLA4 and GM-CSF
- Vectorized Treg-depleting αCTLA-4 elicits antigen cross-presentation and CD8+ T cell immunity to reject “cold” tumors
Semmrich M, Marchand J, Fend L, et al
Journal for ImmunoTherapy of Cancer
Download the publication here
Publication - 3D organoids derived from patients’ lung tumors: a tool for investigating the potential of oncolytic viruses
Hélène Lê et al.
EUROoCS 2021
Download the Poster here
Poster Presentation - BT-001, an oncolytic vaccinia virus armed with a Treg-depleting human recombinant anti-CTLA4 antibody and GM-CSF to target the tumor microenvironment
M. Semmrich et al.
SITC 2020
Download the poster here
Poster Presentation - BT-001, an oncolytic Vaccinia virus armed with a Treg-depletion-optimized recombinant human anti-CTLA4 antibody and GM-CSF to target the tumor microenvironment
Jean-Baptiste Marchand et al.
AACR 2020
Download the poster here
Poster Presentation - BT-001, an oncolytic Vaccinia virus armed with a Treg-depletion-optimized recombinant human anti- CTLA4 antibody and GM-CSF to target the tumor microenvironment
Marchand, Semmrich, Fend et al.
Immuno-Oncology summit
Download the poster here
Poster Presentation
- TG6050 an oncolytic vaccinia virus armed with interleukin 12 and anti-CTLA4 antibody induces TME remodeling and strong anti-tumoral responses
JB. Marchand et al.
AACR 2023
Download the poster here
Poster Presentation
- Oncolytic virus TG6002 safety and activity after intrahepatic artery administration in patients with liver-dominant metastatic colorectal cancer
A. Samson et al.
AACR 2023
Download the poster here
Poster Presentation - Updated data of biodistribution and activity of oncolytic virus TG6002 after intravenous administration in patients with advanced gastrointestinal carcinomas
V. Moreno et al.
ESMO 2022
Download the poster here
Poster Presentation - 3D organoids derived from patients’ lung tumors: a tool for investigating the potential of oncolytic viruses
Hélène Lê et al.
EUROoCS 2021
Download the Poster here
Poster Presentation - High Oncolytic Activity of a Double-Deleted Vaccinia Virus Copenhagen Strain against Malignant Pleural Mesothelioma
Tiphaine Delaunay, et al.
Molecular Therapy Oncolytics, September 2020 – Read the article and view videos
Publication - Preclinical Evaluation of the Oncolytic Vaccinia Virus TG6002 by Translational Research on Canine Breast Cancer
Jérémy Béguin, et al.
Molecular Therapy Oncolytics, September 2020 – Read the article
Publication - Safety studies and viral shedding of intramuscular administration of oncolytic vaccinia virus TG6002 in healthy beagle dogs
Jérémy Béguin, et al.
BMC Vet Res., August 25 2020 – Read the article
Publication - TG6002: a novel oncolytic and vectorized gene-prodrug therapy approach to treat glioblastoma
Johann Foloppe, et al.
International Oncolytic Virus Conference, April 2018
Download the poster here
Poster Presentation - Immune Checkpoint Blockade, Immunogenic Chemotherapy or IFN-α Blockade Boost the Local and Abscopal Effects of Oncolytic Virotherapy
Laetitia Fend, et al.
Cancer Research, July 2017, DOI: 10.1158/0008-5472.CAN-16-2165 – Download the article
Publication - TG6002: A novel oncolytic and vectorized gene pro-drug therapy approach to treat glioblastoma
Ahmed Idbaih, et al.
ASCO 2017, June 2017 – Download the abstract
Abstract - Vectorized gene therapy of liver tumors: proof-of-concept of TG4023 (MVA-FCU1) in combination with flucytosine
Faleh Husseini, et al.
Annals of Oncology, February 2017, DOI: https://doi.org/10.1093/annonc/mdw440 – Download the article
PublicationTG4023 is a non-replicative MVA integrating the FCU1 gene that has been inserted in the oncolytic virus TG6002.
- Oncolytic vaccinia virus TG6002 demonstrates potent efficiency in pancreatic tumor alone and in combination with standard chemotherapies
Johann Foloppe, et al.
XXI International Poxvirus, Asfavirus and Iridovirus Conference Le Bischenberg (France) 1-5 July 2016
Download the poster here
Poster Presentation - Combination of the oncolytic vaccinia virus TG6002 with conventional chemotherapeutic agents in human tumor models resistant to viral oncolysis.
Johann Foloppe, et al.
8th International Conference on Oncolytic Virus Therapeutics. 10-13 April 2014, Oxford, United Kingdom, Abst. 64
Download the poster here
Poster Presentation
- Personalized vaccine TG4050 induces polyepitopic immune responses against private neoantigens in resected HPV negative head and neck cancers
A. Lalanne, et al.
AACR 2024
Abstract available on the AACR website – Download the poster
Poster Presentation - Phase Ib/II trial of tipapkinogene sovacivec (TG4001), a therapeutic human papillomavirus 16-vaccine, in combination with avelumab in patients with advanced human papillomavirus 16-positive cancers
C. Le Tourneau, et al.
European Journal of Cancer, July 2023 (191)
Access the article here
Publication - Safety and Immunogenicity of TG4050; a personalized cancer vaccine in head and neck carcinoma
C. Ottensmeier, et al.
ASCO 2023
Abstract available on the ASCO website – Download the abstract and the poster
Poster Presentation - Immunogenicity and clinical activity of Tipapkinogen sovacivec (TG4001), an HPV-16 cancer vaccine: a randomized phase 2 study in recurrent or metastatic (R/M) anogenital cancers
- Advanced patient-derived lung tumoroids to identify limiting factors for oncolytic virotherapy
H. Le et al.
AACR 2023
Download the poster here
Poster Presentation - PoxSTG, a novel chimeric poxvirus with improved oncolytic potency
P Erbs et al.
AACR 2023
Download the poster here
Poster Presentation - Oncolytic virus TG6002 safety and activity after intrahepatic artery administration in patients with liver-dominant metastatic colorectal cancer
A. Samson et al.
AACR 2023
Download the poster here
Poster Presentation - Feasibility and immunogenicity of adjuvant TG4050, a patient tailored cancer vaccine in head and neck and ovarian cancer
A. Lalane et al.
AACR 2023
Download the poster here
Poster Presentation - A randomized phase II trial of TG4001 plus avelumab versus avelumab alone in recurrent/metastatic (R/M) human papilloma virus (HPV)-16 positive anogenital cancers
C. Le Tourneau et al.
AACR 2023
Download the poster here
Poster Presentation - Selection of an optimal anti-PD-L1 single domain antibody format for the vectorization into oncolytic vaccinia virus and the generation of bispecific immunomodulators
JB. Marchand et al.
AACR 2023
Download the poster here
Poster Presentation - TG6050 an oncolytic vaccinia virus armed with interleukin 12 and anti-CTLA4 antibody induces TME remodeling and strong anti-tumoral responses
JB. Marchand et al.
AACR 2023
Download the poster here
Poster Presentation - Extracellular vesicles (EV): mediators of therapeutic vaccination? In vivo and in vitro characterization of EVs generated after infection of human and murine cells with therapeutic poxviruses
L. Walther et al.
AACR 2023
Download the poster here
Poster Presentation - Updated data of biodistribution and activity of oncolytic virus TG6002 after intravenous administration in patients with advanced gastrointestinal carcinomas
V. Moreno et al.
ESMO 2022
Download the poster here
Poster Presentation - Phase 1 studies of personalized neoantigen vaccine TG4050 in ovarian carcinoma (OC) and head and heck carcinoma (HNSCC)
JP Delord, et al.
ASCO 2022
Abstract available on the ASCO website – Download the poster here
Poster Presentation - Pseudocowpox virus, a novel vector to enhance the therapeutic efficacy of antitumor vaccination
Rodrigo Nalio Ramos, et al.
Clinical and Translational Immunology, May 8 2022 – Read the article
Publication - Comprehensive preclinical studies of BT-001: an oncolytic vaccinia virus armed with Treg-depleting @CTLA4 and GM-CSF
- Phase I trials of personalized cancer vaccine TG4050 in surgically treated high-risk head and neck squamous cell carcinoma (HNSCC) and relapsing ovarian cancer (OvC) patients
- Vectorized Treg-depleting αCTLA-4 elicits antigen cross-presentation and CD8+ T cell immunity to reject “cold” tumors
Semmrich M, Marchand J, Fend L, et al
Journal for ImmunoTherapy of Cancer
Download the publication here
Publication - Bioavailability and activity of oncolytic virus TG6002 after intravenous administration in patients with advanced gastrointestinal carcinomas
P. Cassier et al.
ESMO 2021
Download the poster here
Poster Presentation - 3D organoids derived from patients’ lung tumors: a tool for investigating the potential of oncolytic viruses
Hélène Lê et al.
EUROoCS 2021
Download the Poster here
Poster Presentation - Oncolytic virus TG6002 locates to tumors after intravenous infusion and induces tumor-specific expression of a functional pro-drug activating enzyme in patients with advanced gastrointestinal carcinomas
- Immunocompetent cancer-on-chip models to assess immuno-oncology therapy
Tengku Ibrahim Maulana, et al.
Adv Drug Deliv Rev., March 30 2021 – Read the article
Publication - Correlation of HPV16 Gene Status and Gene Expression With Antibody Seropositivity and TIL Status in OPSCC
Adrian von Witzleben, et al.
Front Oncol., January 26 2021 – Read the article
Publication - Safety, biodistribution and viral shedding of oncolytic vaccinia virus TG6002 administered intravenously in healthy beagle dogs
Jérémy Béguin, et al.
Sci Rep., January 26 2021 – Read the article
Publication - Fluorescent Tagged Vaccinia Virus Genome Allows Rapid and Efficient Measurement of Oncolytic Potential and Discovery of Oncolytic Modulators
Franck Gallardo, et al.
Biomedicines, November 26 2020 – Read the article
Publication - BT-001, an oncolytic vaccinia virus armed with a Treg-depleting human recombinant anti-CTLA4 antibody and GM-CSF to target the tumor microenvironment
M. Semmrich et al.
SITC 2020
Download the poster here
Poster Presentation - TG4001 (Tipapkinogene sovacivec) and avelumab for recurrent/metastatic (R/M) Human Papilloma Virus (HPV)-16+ cancers: clinical efficacy and immunogenicity
C. Le Tourneau et al.
SITC 2020
Download the poster here
Poster Presentation - High Oncolytic Activity of a Double-Deleted Vaccinia Virus Copenhagen Strain against Malignant Pleural Mesothelioma
Tiphaine Delaunay, et al.
Molecular Therapy Oncolytics, September 2020 – Read the article and view videos
Publication - Preclinical Evaluation of the Oncolytic Vaccinia Virus TG6002 by Translational Research on Canine Breast Cancer
Jérémy Béguin, et al.
Molecular Therapy Oncolytics, September 2020 – Read the article
Publication - Safety studies and viral shedding of intramuscular administration of oncolytic vaccinia virus TG6002 in healthy beagle dogs
Jérémy Béguin, et al.
BMC Vet Res., August 25 2020 – Read the article
Publication - Design of an Innovative Model to Improve Anticancer Therapeutic Treatment Based on a Vascularized 3D Organoids Derived from Patients’ Lung Tumors for the Purpose of Precision Medicine
H. Le et al.
EUROoCS 2020
Download the poster here
Poster Presentation - Performance of neoantigen prediction for the design of TG4050, a patient specific neoantigen cancer vaccine
B. Mallone et al.
AACR 2020
Download the poster here
Poster Presentation - BT-001, an oncolytic Vaccinia virus armed with a Treg-depletion-optimized recombinant human anti-CTLA4 antibody and GM-CSF to target the tumor microenvironment
Jean-Baptiste Marchand et al.
AACR 2020
Download the poster here
Poster Presentation - Oncolytic Vaccinia Virus expressing Cytidine Deaminase induces DNA damage and shows potent anti-tumor effects
J. Foloppe et al.
AACR 2020
Download the poster here
Poster Presentation - BT-001, an oncolytic Vaccinia virus armed with a Treg-depletion-optimized recombinant human anti- CTLA4 antibody and GM-CSF to target the tumor microenvironment
Marchand, Semmrich, Fend et al.
Immuno-Oncology summit
Download the poster here
Poster Presentation - Non-clinical and clinical safety of MVA-based immunotherapy products targeting cancer and infectious diseases
Clémentine Spring-Giusti et al.
American College of Toxicology – 40th Annual Meeting
Download the poster here
Poster Presentation - Meta analysis of two phase 1b randomized, double blind, placebo controlled clinical trials of the HBV therapeutic vaccines TG1050 and T101 developed in Europe/Canada or China
Fabien Zoulim et al.
AASLD 2019
Download the poster here
Poster Presentation - Oncolytic Vaccinia virus contains a potent CD80/CD86 ligand whose deletion confers higher tolerance, and potential synergy with immune arming
Jean-Baptiste Marchand et al.
SITC 2019
Download the poster here
Poster Presentation - Phase Ib/II trial of TG4001 (Tipapkinogene sovacivec), a therapeutic HPV-vaccine, and Avelumab in patients with recurrent/metastatic HPV16 positive cancers
Christophe Le Tourneau et al.
ESMO 2019
Download the poster here
Poster Presentation - The efficacy and safety of Tipapkinogen Sovacivec (TG4001) therapeutic HPV vaccine in cervical intraepithelial neoplasia grades 2 and 3: Randomized controlled phase II trial with 2.5 years of follow-up
Diane M. Harper, et al.
Gynecologic Oncology, April 2019 – Download the article
The publication has been featured in The Lancet Oncology and Medpage Today
Publication - The Enhanced Tumor Specificity of TG6002, an Armed Oncolytic Vaccinia Virus Deleted in Two Genes Involved in Nucleotide Metabolism
Johann Foloppe, et al.
Molecular Therapy Oncolytics, March 2019 – Download the article
Publication - Investigational treatment combining TG1050, an HBV-specific immunotherapeutic, with direct acting antivirals or immunomodulators, improves sustained antiviral effects and immune responses in HBV-persistent mice
Roland Kratzer, et al.
AASLD, The Liver Meeting 2018, November 2018 – Abstract available on the AASLD website
Download the poster here
Poster PresentationCollaboration between Transgene – Laboratoire de Recherches Biochirurgicales, Université Paris Descartes, Hôpital Européen Georges Pompidou, Paris, France – Université Paris Diderot, Sorbonne Paris Cité, Paris, France – Hôpital Saint-Louis, Assistance Publique-Hôpitaux de Paris (AP-HP), Paris, France – Alnylam Pharmaceuticals, Cambridge, USA – The State Key Laboratory of Anti-Infection Drug Development, HEC Pharma Group, Dong Guan, China
- Safety and Immunogenicity of Single and Multiple Injections of the Therapeutic Vaccine TG1050 in NUC-Suppressed Chronic Hepatitis B (CHB) Patients: Unblinded Analysis of a Double-Blind, Placebo-Controlled Phase 1b Study
Claire Fournier, et al.
AASLD, The Liver Meeting 2018, November 2018 – Abstract available on the AASLD website
Download the poster here
Poster Presentation - myvac™ Viral based vaccine for personalized neoantigen-directed cancer therapy
Christian Ottensmeier, et al.
SITC 2018, November 2018 – Abstract available on the SITC website
Download the poster here
Poster PresentationCollaboration between Transgene – University of Southampton, United Kingdom – La Jolla Institute for allergy and immunology, USA – University of Copenhagen, Denmark
- Pseudocowpox virus (PCPV), a potent viral vector for both antigen-dependent and independent cancer immunotherapy
Karola Rittner, et al.
SITC 2018, November 2018 – Abstract available on the SITC website
Download the poster here
Poster Presentation - Antibody-armed oncolytic Vaccinia virus to block immunosuppressive pathways in the tumor microenvironment
Jean-Baptiste Marchand et al.
SITC 2018, November 2018 – Abstract available on the SITC website
Download the poster here
Poster PresentationCollaboration between Transgene – BioInvent International A.B, Sweden
- Single intravenous preoperative administration of the oncolytic virus Pexa-Vec to prime anti-tumor immunity
Alan Anthoney, et al.
ASCO 2018, June 2018 – Abstract available on the ASCO website
Download the poster here
Poster Presentation - A multi-antigenic MVA vaccine increases efficacy of combination chemotherapy against Mycobacterium tuberculosis
Stephane Leung-Theung-Long, et al.
PLOS One, May 2018 – Download the article
Publication - Pseudocowpox: A next generation viral vector for cancer immunotherapy
Karolina Rittner, et al.
AACR 2018, April 2018 – Abstract available on the AACR 2018 website
Download the poster here
Poster Presentation - TG6002: a novel oncolytic and vectorized gene-prodrug therapy approach to treat glioblastoma
Johann Foloppe, et al.
International Oncolytic Virus Conference, April 2018
Download the poster here
Poster Presentation - TG1050 is well tolerated and induces a strong specific immune response in patients with chronic hepatitis B
Martin F. Sprinzl, et al.
AASLD & Hepatology, October 2017
Download the poster here
Poster Presentation - Viral based vaccine TG4010 induces broadening of specific immune response and improves outcome in advanced NSCLC
Caroline Tosch, et al.
Journal for ImmunoTherapy of Cancer, 2017, 5:70 – Download the article
Publication - Sequential administration of MVA-based vaccines and PD-1/PD-L1-blocking antibodies confers measurable benefits on tumor growth and survival: preclinical studies with MVA-βGal and MVA-MUC1 (TG4010) in a murine tumor model
Christelle Remy-Ziller, et al.
Human Vaccines & Immunotherapeutics, 2017, 19:0 – Download the article
Publication - A phase Ib trial of JX-594 (Pexa-Vec), a targeted multimechanistic oncolytic vaccinia virus, in combination with low-dose cyclophosphamide in patients with advanced solid tumors
Maud Toulmonde, et al.
ESMO 2017, September 11, 2017, 13:15 – 14:15, Hall 8
Download the poster here
Poster Presentation - Modified Vaccinia virus Ankara-based vaccines in the era of personalized immunotherapy of cancer
K. Bendjama, E. Quéméneur
Human Vaccines and Immunotherapeutics, August 2017 – Read the article
Publication - Immune Checkpoint Blockade, Immunogenic Chemotherapy or IFN-α Blockade Boost the Local and Abscopal Effects of Oncolytic Virotherapy
Laetitia Fend, et al.
Cancer Research, July 2017, DOI: 10.1158/0008-5472.CAN-16-2165 – Download the article
Publication - TG6002: A novel oncolytic and vectorized gene pro-drug therapy approach to treat glioblastoma
Ahmed Idbaih, et al.
ASCO 2017, June 2017 – Download the abstract
Abstract - Local and Abscopal Effects in Oncolytic Virotherapy are boosted by Immune Checkpoint Blockade, Immunogenic Chemotherapy, or IFNAR blockade
Laetitia Fend, et al.
AACR, American Association for cancer Research, April 2017
Download the poster here
Poster Presentation - In situ Biomarker analysis in cancer Immunotherapy: development of quantitative multiplex IHC
Sandrine Cochin, et al.
CLARA, Forum de la recherche en cancérologie, April 2017
Download the poster here
Poster Presentation - Vectorized gene therapy of liver tumors: proof-of-concept of TG4023 (MVA-FCU1) in combination with flucytosine
Faleh Husseini, et al.
Annals of Oncology, February 2017, DOI: https://doi.org/10.1093/annonc/mdw440 – Download the article
PublicationTG4023 is a non-replicative MVA integrating the FCU1 gene that has been inserted in the oncolytic virus TG6002.
- Radiotherapy and MVA-MUC1-IL-2 vaccine act synergistically for inducing specific immunity to MUC-1 tumor antigen
Gilda G. Hillman, et al.
Journal for ImmunoTherapy of Cancer, January 2017 – Download the article
Publication - TG1050, an HBV-targeted immunotherapeutics, efficiently decreases HBV viremia and antigenemia in a preclinical model; a meta-analysis and the determination of the involvement of CD4 and CD8 T cells.
Roland Kratzer, et al.
AASLD & Hepatology, October 2016 – DOI: 10.1002/hep.28800
Download the poster here
Poster Presentation - Vectorization in an oncolytic vaccinia virus of an antibody, a Fab and a scFv against programmed cell death -1 (PD-1) allows their intratumoral delivery and an improved tumor-growth inhibition
Patricia Kleinpeter, et al.
OncoImmunology, October 2016 – Download the article
Publication - Engineering Oncolytic Vaccinia Virus with Improved Cancer Killing Abilities
Johann Foloppe, et al.
10th International Meeting on Replicating Oncolytic Virus Therapeutics, Vancouver, Canada – 1-4 October 2016
Download the poster here
Poster PresentationCollaboration between Transgene – HTS facility IGBMC, Illkirch – France IREBS, Illkirch, France – ICube, Strasbourg, France
- Oncolytic vaccinia virus TG6002 demonstrates potent efficiency in pancreatic tumor alone and in combination with standard chemotherapies
Johann Foloppe, et al.
XXI International Poxvirus, Asfavirus and Iridovirus Conference Le Bischenberg (France) 1-5 July 2016
Download the poster here
Poster Presentation - Evaluation of a novel oncolytic Raccoonpox virus expressing the bifunctional FCU1 suicide gene
Marine Ricordel, et al.
XXI International Poxvirus, Asfavirus and Iridovirus Conference Le Bischenberg (France) 1-5 July 2016
Download the poster here
Poster Presentation - Vectorization in an oncolytic vaccinia virus of an antibody, a Fab and a scFv against programmed cell death-1 (PD-1) allow their intratumoral delivery and an improved tumor growth inhibition
Jean Baptiste Marchand, et al.
XXI International Poxvirus, Asfavirus and Iridovirus Conference Le Bischenberg (France) 1-5 July 2016
Download the poster here
Poster Presentation - Improvement of MVA-based Vaccines by Expression of an Autophagy Inhibitor
Anita Spindler, et al.
XXI International Poxvirus, Asfavirus and Iridovirus Conference Le Bischenberg (France) 1-5 July 2016
Download the poster here
Poster Presentation - A Phase 3 Randomized, Open-Label Study Comparing Pexa-Vec (Vaccinia GM-CSF / Thymidine Kinase-Deactivated Virus) Followed by Sorafenib Versus Sorafenib in Patients with Advanced Hepatocellular Carcinoma (HCC) Without Prior Systemic Therapy
Ghassan K. Abou-Alfa, et al.
ASCO Annual Meeting 2016, June 3-7, 2016, Chicago Illinois
Download the poster here
Poster Presentation - Vectorization in an oncolytic vaccinia virus of an antibody, a Fab and a scFv against programmed cell death -1 (PD-1) allow their intratumoral delivery and an improved tumor-growth inhibition
Jean Baptiste Marchand, et al.
AACR Annual Meeting 2016, April 16-20, 2016, E.N. MorialConvention Center, New Orleans, Louisiana
Download the poster here
Poster Presentation - TG4010 immunotherapy and first-line chemotherapy for advanced non-small-cell lung cancer (TIME): results from the phase 2b part of a randomised, double-blind, placebo-controlled, phase 2b/3 trial
Elisabeth Quoix, et al.
The Lancet Oncology, December 2015, 17: 212–23 – Download the article
Publication - A Novel MVA-Based Multiphasic Vaccine for Prevention or Treatment of Tuberculosis Induces Broad and Multifunctional Cell-Mediated Immunity in Mice and Primates
Stephane Leung-Theung-Long, et al.
PLOS One, November 24, 2015 DOI: 10.1371/journal.pone.0143552 – Download the article
Publication - TG4010 immunotherapy plus chemotherapy as first-line treatment of advanced NSCLC: Phase 2b Results of the TIME trial
John Nemunaitis, et al.
SITC 2015, November 2015 – Abstract available on the SITC website
Download the poster here
Poster Presentation - Recognition of core-derived epitopes from a novel HBV-targeted immunotherapeutic by T-cells from patients infected by different viral genotypes.
Ophelie Godon, et al.
Vaccine. 2015 Aug 26;33(36):4548-53 – Download the article
Publication - TG4010 Immunotherapy plus Chemotherapy as First Line Treatment of Advanced NSCLC: Phase 2b Results.
Elisabeth Quoix, et al.
16th World Conference on Lung Cancer. September 2015, Denver, Colorado
Download the poster here
Poster Presentation - Results of the Phase 2B Part of Time Study Evaluating TG4010 Immunotherapy in Stage IV Non-Small Cell Lung Cancer (NSCLC) Patients Receiving First-Line Chemotherapy
Elisabeth Quoix, et al.
ASCO Annual Meeting 2015 – May 29-June 2, 2015 – Chicago, Illinois
Download the poster here
Poster Presentation - TG1050, a Novel Immunotherapeutic to Treat Chronic Hepatitis B, can Control HBsAg and Provoke HBsAg Seroconversion in HBV-Persistent Mouse Models
Karine Lélu, et al.
Journal of Hepatology, April 2015, Volume 62, Supplement 2, Page S205 – Download the article
Publication - TG1050, a Novel Immunotherapeutic to Treat Chronic Hepatitis B, can Control HBsAg and Provoke HBsAg Seroconversion in HBV-Persistent Mouse Models
Karine Lélu, et al.
EASL Liver Congress 2015, Vienna-23th April 2015
Download the poster here
Poster Presentation - Immune checkpoint inhibitors enhance benefits of modified vaccinia virus Ankara to improve survival in preclinical models of cancer
Karola Rittner, et al.
AACR Annual Meeting, Philadelphia, PA, USA, 18-22 April 2015, Abst. 2497
Download the posterhere
Poster Presentation - The MVA viral platform for the treatment of cancer and chronic infectious diseases: Clinical experience from four randomized controlled phase II studies
Jean-Marc Limacher, et al.
AACR Annual Meeting, Philadelphia, PA, USA, 18-22 April 2015, Abst. 2498.
Download the poster here
Poster Presentation - Viral hepatitis: HBV cure—can we pin our hopes on immunotherapy ?
Hung-Chih Yang, et al.
Nature Reviews Gastroenterology & Hepatology (2015) doi:10.1038/nrgastro.2015.8 – Download the article
Publication - TG1050, an immunotherapeutic to treat chronic hepatitis B, induces robust T cells and exerts an antiviral effect in HBV-persistent mice.
Martin P, Dubois, et al.
Gut. 2014 Nov 26, doi: 10.1136/gutjnl-2014-308041 – Download the article
Publication - TG4010 Immunotherapy Combined with First-line Therapy in Advanced Non- Small Cell Lung Cancer (NSCLC). Phase 2b Results of the TIME Study
Elisabeth Quoix, et al.
Journal for Immunotherapy of Cancer, 2014, 2 (suppl. 3), O12 – Download the article
Publication - TIME: A Phase 2b/3 Evaluating TG4010 in Combination with First-line Therapy in Advanced Non-Small Cell Lung Cancer (NSCLC). Phase 2b results.
Elisabeth Quoix, et al.
ESMO 2014 Congress, Madrid, Spain, 26-30 September 2014, Abst. 5152
Download the poster here
Poster Presentation - Efficacy of immunotherapy with TG4040, Peg-interferon, and ribavirin in A phase 2 study of patients with chronic HCV infection.
Adrian Di Bisceglie, et al.
Gastroenterology, 2014; Mar 18 – Download the article
Publication - Comparative analysis of immunization schedules using a novel adenovirus – based immunotherapeutic targeting hepatitis B in naïve and tolerant mouse models.
Houda Boukhebza, et al.
Vaccine. 2014, 32(26):3256-63. – Download the article
Publication - Combination of the oncolytic vaccinia virus TG6002 with conventional chemotherapeutic agents in human tumor models resistant to viral oncolysis.
Johann Foloppe, et al.
8th International Conference on Oncolytic Virus Therapeutics. 10-13 April 2014, Oxford, United Kingdom, Abst. 64
Download the poster here
Poster Presentation - Immunological characterization of a modified vaccinia virus Ankara vector expressing the human papillomavirus 16 E1 protein.
Christelle Remy-Ziller, et al.
Clinical and vaccine immunology. 2014; 21(2): 147-155 – Download the article
Publication - Immunotherapy for non – small – cell lung cancer: current approaches.
Elisabeth Quoix, et al.
Current Respiratory Care Reports, 2014; 3 (1): 19-25 – Download the article
Publication - Preclinical evaluation of MVA-MUC1-IL2 in combination with chemotherapy in murine models.
Micaël De Meyer, et al.
Journal for Immunotherapy of Cancer, 2013 – Download the article
Publication - TG1050, A viral-vector based immunotherapeutic designed to treat chronic hepatitis B induces immune responses similar to those display by HBV resolving patients and has an early antiviral effects in a HBV tolerant model.
Perrine Martin, et al.
Hepatology, 2013, (58) S1, 222A–225A – Download the article
Publication - Pre-clinical proof-of-concept studies exploring schedules of administration of an adenovirus-based HBV immunotherapeutic show wide potential for induction of robust and long-lasting T-cell responses.
Houda Boukhebza, et al.
Journal of Hepatology, 2013, (58), Supplement 1, S161 – Download the article
Publication - 130 – A multivalent adenovirus-based immunotherapeutic for treatment of chronic hepatitis B induces broad, robust and polyfunctional T cells in naive and HBV tolerant mice.
Perrine Martin, et al.
Journal of Hepatology, 2013, (58), Supplement 1, S57–S58. – Download the article
Publication - Phase II trial of Pexa-Vec (pexastimogene devacirepvec; JX-594), an oncolytic and immunotherapeutic vaccinia virus, followed by sorafenib in patients with advanced hepatocellular carcinoma (HCC)
J. Heo, C. Breitbach, M. Cho, T.H. Hwang, C.W. Kim, U.B. Jeon, H.Y. Woo, K.T. Yoon, J.W. Lee, J. Burke, T. Hickman, K. Dubois, L. Longpre, R. Patt, D.H. Kirn
Journal of clinical Oncology, 2013, 31, (suppl; abstr 4122)
[Publication] - Phase Ib dose-escalation study of Pexa-Vec (pexastimogene devacirepvec; JX-594), an oncolytic and immunotherapeutic vaccinia virus, administered by intravenous (IV) infusions in patients with metastatic colorectal carcinoma (mCRC)
J. Lee J, S.Y. Park, J. Burke, H.Y. Lim, J. Lee, W.K. Kang, J.O. Park, A. Pelusio, C. Breitbach, D.H. Kirn
Journal of clinical Oncology, 2013, 31, (suppl; abstr 3608)
[Publication] - Oncolytic and immunotherapeutic vaccinia induces antibody-mediated complement-dependent cancer cell lysis in humans
Mi Kyung Kim, et al.
Science Translational Medicine. 2013 May 15;5(185):185ra63 – Download the article
Publication - Randomized dose-finding clinical trial of oncolytic immunotherapeutic vaccinia JX-594 in liver cancer
Jeong Heo, et al.
Nature Medicine, 2013 (3):329-36. doi: 10.1038/nm.3089. Epub 2013 Feb 10. – Download the article
Publication - Therapeutic cancer vaccines in the treatment of non-small cell lung cancer
Jean-Marc Limacher, et al.
Expert Review of Vaccines, 2013; 12(3): 263-270 – Download the article
Publication
